Biowarfare and Bioterrorism

Critical Care Clinics

Volumn 29, Issue 3, 2013, Pages 717-756

  Christian, Michael D ^a,b  

^a DEPARTMENT OF NATIONAL DEFENCE   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Anthrax; Bioterrorism; Bioweapon; Critical care; Mass casualty; Smallpox

Indexed keywords

ANTIBIOTIC AGENT; BOTULINUM TOXIN; CONOTOXIN; MYCOTOXIN; NICOTINE; RICIN; SAXITOXIN; STAPHYLOCOCCUS ENTEROTOXIN; TETRODOTOXIN;

ANTHRAX; ANTIBIOTIC THERAPY; ARMY; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE; BIOLOGICAL WARFARE AGENT; BIOWARFARE; BOTULISM; BRUCELLA; BURKHOLDERIA; BURKHOLDERIA MALLEI; BURKHOLDERIA PSEUDOMALLEI; CLOSTRIDIUM PERFRINGENS; CLOSTRIDIUM PERFRINGENS INFECTION; COXIELLA BURNETII; CRIMEAN CONGO HEMORRHAGIC FEVER; DENGUE; EBOLA HEMORRHAGIC FEVER; ESCHERICHIA COLI O157; FRANCISELLA TULARENSIS; HANTAVIRUS PULMONARY SYNDROME; HEMORRHAGIC FEVER WITH RENAL SYNDROME; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION PREVENTION; INTENSIVE CARE; LISTERIA MONOCYTOGENES; MASS DISASTER; MELIOIDOSIS; MOLLUSCUM CONTAGIOSUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHYSICIAN; PLAGUE; PNEUMONIA; PRIORITY JOURNAL; Q FEVER; REVIEW; RIFT VALLEY FEVER; SALMONELLA; SEPTIC SHOCK; SHIGELLA; SMALLPOX; SMALLPOX VIRUS; TREATMENT RESPONSE; TULAREMIA; VACCINATION; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS HEMORRHAGIC FEVER; WASTE MANAGEMENT; YERSINIA PESTIS;

ANTHRAX; BIOTERRORISM; BIOWEAPON; CRITICAL CARE; MASS CASUALTY; SMALLPOX;

ANIMALS; ANTHRAX; BIOLOGICAL WARFARE AGENTS; BIOTERRORISM; COCCIDIOIDOMYCOSIS; CRITICAL CARE; DISEASE OUTBREAKS; HEMORRHAGIC FEVERS, VIRAL; HUMANS; INSECTS; MASS CASUALTY INCIDENTS; NOXAE; PLAGUE; Q FEVER; SMALLPOX; TOXINS, BIOLOGICAL; TULAREMIA;

EID: 84879997600     PISSN: 07490704     EISSN: 15578232     Source Type: Journal    
DOI: 10.1016/j.ccc.2013.03.015     Document Type: Review

References (64)

1. Bush L.M., Abrams B.H., Beall A., et al. Index case of fatal inhalational anthrax due to bioterrorism in the United States. NEngl J Med 2001, 345(22):1607-1610.
2. Bush L.M., Perez M.T. The anthrax attacks 10 years later. Ann Intern Med 2012, 156(1 Pt 1):41-44.
3. Kadlec R.P., Zelicoff A.P., Vrtis A.M. Biological weapons control. Prospects and implications for the future. JAMA 1997, 278(5):351-356.
4. Spencer R.C. Potential bio-terror agents. JHosp Infect 2007, 65(Suppl 2):19-22.
5. Gyles C. Agroterrorism. Can Vet J 2010, 51(4):347-348.
6. Monthei D., Mueller S., Lockwood J., et al. Entomological terrorism: a tactic in asymmetrical warfare. US Army Med Dep J 2010, 11-21.
7. Karwa M., Currie B., Kvetan V. Bioterrorism: preparing for the impossible or the improbable. Crit Care Med 2005, 33(Suppl):S75-S95.
8. Graham B., Talent J. The threat of bioterrorism. Disaster Med Public Health Prep 2011, 5(Suppl 2):S170-S171.
9. Inglesby T.V., O'Toole T., Henderson D.A., et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002, 287:2236-2252.
10. Relman D.A. Bioterrorism-preparing to fight the next war. NEngl J Med 2006, 354(2):113-115.
11. Sweeney D.A., Hicks C.W., Cui X., et al. Anthrax infection. Am J Respir Crit Care Med 2011, 184(12):1333-1341.
12. Hicks C.W., Sweeney D.A., Cui X., et al. An overview of anthrax infection including the recently identified form of disease in injection drug users. Intensive Care Med 2012, 38(7):1092-1104.
13. Meselson M., Guillemin J., Hugh-Jones M., et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994, 266(5188):1202-1208.
14. Jernigan J.A., Stephens D.S., Ashford D.A., et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001, 7(6):933-944.
15. Krauter P., Tucker M. Abiological decontamination process for small, privately owned buildings. Biosecur Bioterror 2011, 9(3):301-309.
16. Kenar L., Ortatatli M., Yaren H., et al. Comparative sporicidal effects of disinfectants after release of a biological agent. Mil Med 2007, 172(6):616-621.
17. Campbell C.G., Kirvel R.D., Love A.H., et al. Decontamination after a release of B. anthracis spores. Biosecur Bioterror 2012, 10(1):108-122.
18. Prentice M.B., Rahalison L. Plague. Lancet 2007, 369(9568):1196-1207.
19. Darling R.G., Catlett C.L., Huebner K.D., et al. Threats in bioterrorism. I: CDC category A agents. Emerg Med Clin North Am 2002, 20(2):273-309.
20. Dennis D.T., Inglesby T.V., Henderson D.A., et al. Tularemia as a biological weapon: medical and public health management. JAMA 2001, 285:2763-2773.
21. Cronquist S.D. Tularemia: the disease and the weapon. Dermatol Clin 2004, 22(3):313-320. vi-vii.
22. Lockwood J.A. Insects as weapons of war, terror, and torture. Annu Rev Entomol 2012, 57(1):205-227.
23. Oyston P.C., Davies C. Qfever: the neglected biothreat agent. JMed Microbiol 2010, 60(1):9-21.
24. Moran G.J. Threats in bioterrorism. II: CDC category B and C agents. Emerg Med Clin North Am 2002, 20(2):311-330.
25. Azad A.F. Pathogenic rickettsiae as bioterrorism agents. Clin Infect Dis 2007, 45(Suppl 1):S52-S55.
26. Larsen J.C., Johnson N.H. Pathogenesis of Burkholderia pseudomallei and Burkholderia mallei. Mil Med 2009, 174(6):647-651.
27. Weiss M.M., Weiss P.D., Mathisen G., et al. Rethinking smallpox. Clin Infect Dis 2004, 39(11):1668-1673.
28. Moore Z.S., Seward J.F., Lane J.M. Smallpox. Lancet 2006, 367(9508):425-435.
29. Mahy B.W. An overview on the use of a viral pathogen as a bioterrorism agent: why smallpox?. Antiviral Res 2003, 57(1-2):1-5.
30. Meltzer M.I., Damon I., LeDuc J.W., et al. Modeling potential responses to smallpox as a bioterrorist weapon. Emerg Infect Dis 2001, 7(6):959-969.
31. Kaufmann A.F., Meltzer M.I., Schmid G.P. The economic impact of a bioterrorist attack: are prevention and postattack intervention programs justifiable?. Emerg Infect Dis 1997, 3(2):83-94.
32. Sidwell R.W., Smee D.F. Viruses of the Bunya- and Togaviridae families: potential as bioterrorism agents and means of control. Antiviral Res 2003, 57(1-2):101-111.
33. Interim guidance for managing patients with suspected viral hemorrhagic fever in US hospitals 2005, US Centers for Disease Control, Atlanta (GA), p. 1-4.
34. Warnock D.W. Coccidioides species as potential agents of bioterrorism. Future Microbiol 2007, 2(3):277-283.
35. Anderson P.D. Bioterrorism: toxins as weapons. JPharm Pract 2012, 25(2):121-129.
36. Farmer B.M., Nelson L.S., Graham M.E., et al. Developing a consensus framework and risk profile for agents of opportunity in academic medical centers: implications for public health preparedness. Disaster Med Public Health Prep 2010, 4(4):318-325.
37. Noah D.L., Huebner K.D., Darling R.G., et al. The history and threat of biological warfare and terrorism. Emerg Med Clin North Am 2002, 20(2):255-271.
38. Radosavljevic V., Belojevic G. Unusual epidemic events: a new method of early orientation and differentiation between natural and deliberate epidemics. Public Health 2012, 126(1):77-81.
39. Gerberding J.L., Hughes J.M., Koplan J.P. Bioterrorism preparedness and response: clinicians and public health agencies as essential partners. JAMA 2002, 287(7):898-900.
40. Bozeman W.P., Dilbero D., Schauben J.L. Biologic and chemical weapons of mass destruction. Emerg Med Clin North Am 2002, 20(4):975-993. xii.
41. Nordin J.D., Goodman M.J., Kulldorff M., et al. Simulated anthrax attacks and syndromic surveillance. Emerg Infect Dis 2005, 11(9):1394-1398.
42. Wong T., Wallington T., McDonald L.C., et al. Late recognition of SARS in nosocomial outbreak, Toronto. Emerg Infect Dis 2005, 11(2):322-325.
43. Christian M.D., Stewart T.E., Lapinsky S.E. Critical care and biological disasters: lessons learned from SARS and pandemic influenza planning. Recent advances in anaesthesia and intensive care 2007, 264. Cambridge University Press, Cambridge (United Kingdom). 24th edition. J. Cashman, M. Grounds (Eds.).
44. Burkle F.M., Hsu E.B., Loehr M., et al. Definition and functions of health unified command and emergency operations centers for large-scale bioevent disasters within the existing ICS. Disaster Med Public Health Prep 2007, 1(2):135-141.
45. Henretig F.M., Cieslak T.J., Kortepeter M.G., et al. Medical management of the suspected victim of bioterrorism: an algorithmic approach to the undifferentiated patient. Emerg Med Clin North Am 2002, 20(2):351-364.
46. Christian M.D., Poutanen S.M., Loutfy M.R., et al. Severe acute respiratory syndrome. Clin Infect Dis 2004, 38(10):1420-1427.
47. NATO handbook on the medical aspects of NBC defensive operations, Part II-Biological 1996, US Department of Defense, Department of the Army, Washington, DC.
48. Karwa M., Bronzert P., Kvetan V. Bioterrorism and critical care. Crit Care Clin 2003, 19(2):279-313.
49. Hupert N., Wattson D., Cuomo J., et al. Predicting hospital surge after a large-scale anthrax attack: a model-based analysis of CDC's cities readiness initiative prophylaxis recommendations. Med Decis Making 2009, 29(4):424-437.
50. Pavlin J.A., Gilchrist M.J., Osweiler G.D., et al. Diagnostic analyses of biological agent-caused syndromes: laboratory and technical assistance. Emerg Med Clin North Am 2002, 20(2):331-350.
51. Wagar E.A., Mitchell M.J., Carroll K.C., et al. Areview of sentinel laboratory performance: identification and notification of bioterrorism agents. Arch Pathol Lab Med 2010, 134(10):1490-1503.
52. Ketai L., Alrahji A.A., Hart B., et al. Radiologic manifestations of potential bioterrorist agents of infection. AJR Am J Roentgenol 2003, 180(3):565-575.
53. Kyriacou D.N., Stein A.C., Yarnold P.R., et al. Clinical predictors of bioterrorism-related inhalational anthrax. Lancet 2004, 364(9432):449-452.
54. Hupert N., Bearman G.M., Mushlin A.I., et al. Accuracy of screening for inhalational anthrax after a bioterrorist attack. Ann Intern Med 2003, 139(5 Pt 1):337-345.
55. Mayer T.A., Morrison A., Bersoff-Matcha S., et al. Inhalational anthrax due to bioterrorism: would current Centers for Disease Control and Prevention guidelines have identified the 11 patients with inhalational anthrax from October through November 2001?. Clin Infect Dis 2003, 36(10):1275-1283.
56. Howell J.M., Mayer T.A., Hanfling D., et al. Screening for inhalational anthrax due to bioterrorism: evaluating proposed screening protocols. Clin Infect Dis 2004, 39(12):1842-1847.
57. Jahrling P.B. Viral hemorrhagic fever. Medical aspects of chemical and biological warfare 1997, 591-602. The Office of The Surgeon General at TMM Publications, Washington, DC. F.R. Sidell, E.T. Takafuji, D.R. Franz (Eds.).
58. Sampath A., Metz M., Stundick M., et al. State-of-the-art therapeutic medical countermeasures for viral threat agents. Biosecur Bioterror 2011, 9(4):351-360.
59. Parcell B.J., Wilmshurst A.D., France A.J., et al. Injection anthrax causing compartment syndrome and necrotising fasciitis. JClin Pathol 2011, 64(1):95-96.
60. Jallali N., Hettiaratchy S., Gordon A.C., et al. The surgical management of injectional anthrax. JPlast Reconstr Aesthet Surg 2011, 64(2):276-277.
61. Anathallee M., Curphey A., Beeching N., et al. Emergency departments (EDs) in the United Kingdom (UK) are not prepared for emerging biological threats and bioterrorism. JInfect 2007, 54(1):12-17.
62. Devereaux A., Christian M.D., Dichter J.R., et al. Summary of suggestions from the Task Force for Mass Critical Care summit, January 26-27, 2007. Chest 2008, 133:1S-7S.
63. Robichaud S., Libman M., Behr M., et al. Prevention of laboratory-acquired brucellosis. Clin Infect Dis 2004, 38(12):e119-e122.
64. Russell P., Eley S.M., Ellis J., et al. Comparison of efficacy of ciprofloxacin and doxycycline against experimental melioidosis and glanders. JAntimicrob Chemother 2000, 45(6):813-818.